JP5634498B2 - 中枢神経系の変性障害の予防および/または治療方法 - Google Patents

中枢神経系の変性障害の予防および/または治療方法 Download PDF

Info

Publication number
JP5634498B2
JP5634498B2 JP2012504880A JP2012504880A JP5634498B2 JP 5634498 B2 JP5634498 B2 JP 5634498B2 JP 2012504880 A JP2012504880 A JP 2012504880A JP 2012504880 A JP2012504880 A JP 2012504880A JP 5634498 B2 JP5634498 B2 JP 5634498B2
Authority
JP
Japan
Prior art keywords
compound
disease
diol
piperidine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012504880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523430A5 (https=
JP2012523430A (ja
Inventor
ロバート・ボイド
ゲイリー・リー
Original Assignee
アミカス セラピューティックス インコーポレイテッド
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミカス セラピューティックス インコーポレイテッド, アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2012523430A publication Critical patent/JP2012523430A/ja
Publication of JP2012523430A5 publication Critical patent/JP2012523430A5/ja
Application granted granted Critical
Publication of JP5634498B2 publication Critical patent/JP5634498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012504880A 2009-04-09 2010-04-09 中枢神経系の変性障害の予防および/または治療方法 Active JP5634498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
US61/168,101 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (3)

Publication Number Publication Date
JP2012523430A JP2012523430A (ja) 2012-10-04
JP2012523430A5 JP2012523430A5 (https=) 2013-05-16
JP5634498B2 true JP5634498B2 (ja) 2014-12-03

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504880A Active JP5634498B2 (ja) 2009-04-09 2010-04-09 中枢神経系の変性障害の予防および/または治療方法

Country Status (11)

Country Link
US (1) US8304429B2 (https=)
EP (1) EP2416655B1 (https=)
JP (1) JP5634498B2 (https=)
CN (1) CN102448306B (https=)
AU (1) AU2010233187B2 (https=)
BR (1) BRPI1015472A2 (https=)
CA (1) CA2758187C (https=)
ES (1) ES2505243T3 (https=)
IL (1) IL215584A (https=)
NZ (1) NZ595630A (https=)
WO (1) WO2010118282A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940766B2 (en) * 2009-04-09 2015-01-27 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
WO2011049737A1 (en) * 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
SI2490532T1 (sl) 2009-10-19 2017-03-31 Amicus Therapeutics, Inc. Novi sestavki za preventivo in/ali zdravljenje degenerativnih motenj centralnega živčnega sistema
CA3077910A1 (en) 2010-11-17 2012-05-24 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
WO2015095963A1 (en) 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN110177572A (zh) * 2016-09-12 2019-08-27 史蒂文·霍夫曼 用于治疗痴呆的组合物
AR110074A1 (es) * 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
BR112020013994A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
EA202091693A1 (ru) 2018-01-12 2021-04-14 Бристол-Маерс Сквибб Компани Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024391A1 (en) * 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー/エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
CN101541172A (zh) * 2005-06-08 2009-09-23 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
JP5303458B2 (ja) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
US8940766B2 (en) * 2009-04-09 2015-01-27 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders

Also Published As

Publication number Publication date
IL215584A (en) 2016-11-30
ES2505243T3 (es) 2014-10-09
US20100261753A1 (en) 2010-10-14
CN102448306B (zh) 2014-07-02
AU2010233187B2 (en) 2015-10-08
EP2416655B1 (en) 2014-06-25
CA2758187C (en) 2017-03-07
US8304429B2 (en) 2012-11-06
EP2416655A1 (en) 2012-02-15
CN102448306A (zh) 2012-05-09
BRPI1015472A2 (pt) 2015-11-24
HK1168005A1 (zh) 2012-12-21
CA2758187A1 (en) 2010-10-14
WO2010118282A1 (en) 2010-10-14
AU2010233187A1 (en) 2011-11-03
EP2416655A4 (en) 2012-09-05
IL215584A0 (en) 2011-12-29
JP2012523430A (ja) 2012-10-04
NZ595630A (en) 2013-04-26

Similar Documents

Publication Publication Date Title
JP5634498B2 (ja) 中枢神経系の変性障害の予防および/または治療方法
JP6258245B2 (ja) 中枢神経系の変性障害を予防および/または治療するための新規の組成物
JP5645918B2 (ja) リソソーム蓄積障害の予防および/または治療方法
HK1168005B (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
HK1175074A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628A1 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130327

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140422

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140718

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141014

R150 Certificate of patent or registration of utility model

Ref document number: 5634498

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250